Difference between revisions of "Combining-Topiramate-Carbamazepine"

From Psychiatrienet
Jump to: navigation, search
 
(One intermediate revision by one other user not shown)
Line 2: Line 2:
 
| base = topiramate
 
| base = topiramate
 
| add = carbamazepine
 
| add = carbamazepine
| info =  
+
| info =  
* Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
 
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
 
* This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
 
 
| start =  
 
| start =  
* Carbamazepine can increase topiramate clearance. Add carbamazepine according to the general dosing advice and check the effects of topiramate and increase dose if necessary. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> <ref name=”bazire”> Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref>
+
* Carbamazepine can increase topiramate clearance. By adding topiramate to carbamazepine no dose adaptation is necessary. <ref name=”bazire”> Bazire S, Pshychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref> <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> <ref name="drugscomint">
| cave =  
+
{{Drugscominteract|carbamazepine-with-topiramate-2216-0-497-0|carbamazepine|topiramate}}</ref>
 +
| cave =
 +
* This combination of drugs is subject to pharmacokinetic drug interactions. Discontinuation or dose reduction of either drug will need monitoring of the clinical effects and dose adaptation of the drug remained.
 
}}
 
}}

Latest revision as of 12:33, 18 June 2010

Topiramate
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX11
PubChem 5284627
PubMed Topiramate
Drugs.com topiramate
Kompas (Dutch) Topiramate
Wikipedia Topiramate
Carbamazepine
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AF01
Medscape Carbamazepine
PubChem 2554
PubMed Carbamazepine
Drugs.com carbamazepine
Kompas (Dutch) Carbamazepine
Wikipedia Carbamazepine

Adding carbamazepine to topiramate.

Infobord.png General information
  • Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
  • Carbamazepine is principally metabolized by CYP3A4, and is a potent inducer of CYP1A2, CYP2C9, CYP3A4 and UDP-glucuronosyltransferases.

 

Eenrichtingbord.png Start carbamazepine
  • Carbamazepine can increase topiramate clearance. By adding topiramate to carbamazepine no dose adaptation is necessary. [5] [6] [7]
Letopbord.png Cave
  • This combination of drugs is subject to pharmacokinetic drug interactions. Discontinuation or dose reduction of either drug will need monitoring of the clinical effects and dose adaptation of the drug remained.


  1. 1.0 1.1 1.2 Farmacotherapeutisch Kompas - topiramaat (dutch) Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content
  2. WHO Collaborating Centre for Drug Statistics Methodology ATC=N03AF01
  3. Farmacotherapeutisch Kompas; Toxicologie (dutch)
  4. KNMP; Informatorium Medicamentorum 2023; Monografie "carbamazepine" (Dutch)
  5. Bazire S, Pshychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007.
  6. Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002.
  7. Interactions between carbamazepine and topiramate on drugs.com
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.